NCT07085104

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2025-11-13Est. Completion: 2028-02

Enrollment target: 66 participants

Locations

Mayo Clinic, Phoenix, Arizona, United States
Loma Linda University Medical Center, Loma Linda, California, United States
University of Colorado Denver, Aurora, Colorado, United States
Mayo Clinic, Jacksonville, Florida, United States
The University of Chicago Medical Center, Chicago, Illinois, United States
University of Iowa, Iowa City, Iowa, United States
University of Kansas Medical Center, Kansas City, Kansas, United States
Norton Cancer Institute, St. Matthews Campus, Louisville, Kentucky, United States
Johns Hopkins Hospital, Baltimore, Maryland, United States
Astera Cancer Care, East Brunswick, New Jersey, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Atrium Health Rheumatology-Southpark, Charlotte, North Carolina, United States
Duke University Medical Center, Durham, North Carolina, United States
Medical University of South Carolina, Charleston, South Carolina, United States
Prisma Health, Greenville, South Carolina, United States
LDS Hospital - lntermountain Health, Salt Lake City, Utah, United States

Lupus Nephritis (LN)Systemic Lupus Erythematosus (SLE)Autoimmune Diseases

This Phase 2, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of autologous ant…

Multiple LocationsEst. completion Dec 31, 2028

Lupus Nephritis

The purpose of this up to 6-year extension study is the evaluation of the efficacy and safety 1. after study treatment …

Orchard Park, United StatesEst. completion Aug 1, 2035

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.